Complacency a risk as companies prepare for future supply chain disruption

12 June 2020

If recent years have taught industries like the pharmaceutical sector anything, it is that they should expect the unexpected, be it global pandemics, Brexit, freak storms or other major health, political or natural phenomena.

As pharma companies seek to prepare for the next such event, they have been warned by a new report that complacency could be the biggest barrier that they will face to prevent them from making supply chain changes.

View the critical report The report, written by industry expert Dr Nicola Davies and entitled COVID-19 and the Pharmaceutical Supply Chain — Riding the Wave and Emerging Stronger, states: “To prevent complacency and other threats to resilience, companies must act on their plans now with both financial and behavioral commitment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK